HK1205941A1 - Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate - Google Patents
Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate Download PDFInfo
- Publication number
- HK1205941A1 HK1205941A1 HK15106555.7A HK15106555A HK1205941A1 HK 1205941 A1 HK1205941 A1 HK 1205941A1 HK 15106555 A HK15106555 A HK 15106555A HK 1205941 A1 HK1205941 A1 HK 1205941A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- laquinimod
- multiple sclerosis
- combination
- dmf
- presenting
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Exchange Systems With Centralized Control (AREA)
- Liquid Crystal Substances (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261616337P | 2012-03-27 | 2012-03-27 | |
| US61/616,337 | 2012-03-27 | ||
| US13/800,047 | 2013-03-13 | ||
| US13/800,047 US20130259856A1 (en) | 2012-03-27 | 2013-03-13 | Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate |
| PCT/US2013/033885 WO2013148690A1 (en) | 2012-03-27 | 2013-03-26 | Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1205941A1 true HK1205941A1 (en) | 2015-12-31 |
Family
ID=49235339
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK15106555.7A HK1205941A1 (en) | 2012-03-27 | 2013-03-26 | Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate |
Country Status (17)
| Country | Link |
|---|---|
| US (6) | US20130259856A1 (https=) |
| EP (1) | EP2830623A4 (https=) |
| JP (2) | JP2015512406A (https=) |
| KR (1) | KR20150003765A (https=) |
| CN (2) | CN105853422A (https=) |
| AR (1) | AR090491A1 (https=) |
| AU (2) | AU2013239850A1 (https=) |
| CA (1) | CA2868259A1 (https=) |
| EA (1) | EA201491773A1 (https=) |
| HK (1) | HK1205941A1 (https=) |
| IL (1) | IL234687A0 (https=) |
| MX (1) | MX2014011616A (https=) |
| SG (2) | SG10201607976WA (https=) |
| TW (1) | TW201343164A (https=) |
| UY (1) | UY34720A (https=) |
| WO (1) | WO2013148690A1 (https=) |
| ZA (1) | ZA201407722B (https=) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2554347C2 (ru) | 2008-08-19 | 2015-06-27 | Ксенопорт, Инк. | Пролекарства метилгидрофумарата, фармацевтические композиции с ними и способы применения |
| CA2851525A1 (en) | 2011-10-12 | 2013-04-18 | Teva Pharmaceutical Industries Ltd. | Treatment of multiple sclerosis with combination of laquinimod and fingolimod |
| US9504679B2 (en) | 2011-12-19 | 2016-11-29 | Bjoern Colin Kahrs | Pharmaceutical compositions comprising glitazones and Nrf2 activators |
| US20130158077A1 (en) | 2011-12-19 | 2013-06-20 | Ares Trading S.A. | Pharmaceutical compositions |
| CN104093310A (zh) | 2012-02-03 | 2014-10-08 | 泰华制药工业有限公司 | 拉喹莫德用于治疗一线抗TNFα疗法失败的克罗恩氏病患者的用途 |
| JP6215238B2 (ja) | 2012-02-16 | 2017-10-18 | テバ ファーマシューティカル インダストリーズ リミティド | Ｎ−エチル−ｎ−フェニル−１，２−ジヒドロ−４，５−ジ−ヒドロキシ−１−メチル−２−オキソ−３−キノリンカルボキサミド、その製剤、および使用 |
| TW201400117A (zh) | 2012-06-05 | 2014-01-01 | Teva Pharma | 使用拉喹莫德治療眼發炎疾病 |
| EP2692343A1 (en) * | 2012-08-03 | 2014-02-05 | Forward Pharma A/S | Combination therapy for treatment of multiple sclerosis |
| TW201410244A (zh) | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ） |
| CA2882730C (en) | 2012-08-22 | 2019-12-31 | Arbor Pharmaceuticals, Llc | Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof |
| US10945984B2 (en) | 2012-08-22 | 2021-03-16 | Arbor Pharmaceuticals, Llc | Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects |
| EP2916915A4 (en) | 2012-11-07 | 2016-06-22 | Teva Pharma | LAQUINIMOD AMINE SALTS |
| US20160046582A1 (en) | 2013-03-14 | 2016-02-18 | Teva Pharmaceutical Industries Ltd. | Crystals of laquinimod sodium and improved process for the manufacture thereof |
| US10179118B2 (en) | 2013-03-24 | 2019-01-15 | Arbor Pharmaceuticals, Llc | Pharmaceutical compositions of dimethyl fumarate |
| US9302977B2 (en) | 2013-06-07 | 2016-04-05 | Xenoport, Inc. | Method of making monomethyl fumarate |
| US9421182B2 (en) | 2013-06-21 | 2016-08-23 | Xenoport, Inc. | Cocrystals of dimethyl fumarate |
| US9416096B2 (en) | 2013-09-06 | 2016-08-16 | Xenoport, Inc. | Crystalline forms of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate, methods of synthesis and use |
| ES2713157T3 (es) | 2014-02-28 | 2019-05-20 | Banner Life Sciences Llc | Cápsulas blandas entéricas de liberación controlada de ésteres de fumarato |
| US9636318B2 (en) | 2015-08-31 | 2017-05-02 | Banner Life Sciences Llc | Fumarate ester dosage forms |
| US9326947B1 (en) | 2014-02-28 | 2016-05-03 | Banner Life Sciences Llc | Controlled release fumarate esters |
| US10098863B2 (en) | 2014-02-28 | 2018-10-16 | Banner Life Sciences Llc | Fumarate esters |
| US9999672B2 (en) | 2014-03-24 | 2018-06-19 | Xenoport, Inc. | Pharmaceutical compositions of fumaric acid esters |
| WO2015168103A1 (en) | 2014-04-29 | 2015-11-05 | Teva Pharmaceutical Industries Ltd. | Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status |
| KR20200013086A (ko) | 2014-12-11 | 2020-02-05 | 액테리온 파마슈티칼 리미티드 | 선택적 s1p1 수용체 효능제에 대한 투약 섭생 |
| MA41139B1 (fr) | 2014-12-11 | 2026-02-27 | Laboratoires Juvise Pharmaceuticals | Combinaison pharmaceutique comprenant du ponesimod et son utilisation dans le traitement de la sclérose en plaque |
| GB2540163A (en) * | 2015-07-07 | 2017-01-11 | Univ London Queen Mary | Combination therapy for treating multiple sclerosis |
| WO2017120355A1 (en) * | 2016-01-06 | 2017-07-13 | Teva Pharmaceutical Industries Ltd. | Dihydroquinolines and uses thereof |
| US11903918B2 (en) | 2020-01-10 | 2024-02-20 | Banner Life Sciences Llc | Fumarate ester dosage forms with enhanced gastrointestinal tolerability |
| US12483171B2 (en) | 2023-12-18 | 2025-11-25 | Abb Schweiz Ag | Plug and play solid state controller for high efficiency motors |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6077851A (en) | 1998-04-27 | 2000-06-20 | Active Biotech Ab | Quinoline derivatives |
| SE0400235D0 (sv) | 2004-02-06 | 2004-02-06 | Active Biotech Ab | New composition containing quinoline compounds |
| WO2007006308A1 (en) * | 2005-07-07 | 2007-01-18 | Aditech Pharma Ab | Novel glucopyranose esters and glucofuranose esters of alkyl- fu marates and their pharmaceutical use |
| NZ567088A (en) | 2005-10-19 | 2012-06-29 | Teva Pharma | Crystals of laquinimod sodium, and process for the manufacture thereof |
| KR20150065951A (ko) | 2006-06-12 | 2015-06-15 | 테바 파마슈티컬 인더스트리즈 리미티드 | 안정한 라퀴니모드 제제 |
| EP2680010A1 (en) * | 2007-02-08 | 2014-01-01 | Biogen Idec MA Inc. | Nrf2 screening assays and related methods and compositions |
| ES2599227T3 (es) * | 2007-02-08 | 2017-01-31 | Biogen Ma Inc. | Neuroprotección en enfermedades desmielinizantes |
| US20100260755A1 (en) * | 2009-04-09 | 2010-10-14 | Medicinova, Inc. | Ibudilast and immunomodulators combination |
| JP2012525385A (ja) * | 2009-04-29 | 2012-10-22 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 神経変性および神経炎症の治療 |
| JP2012530701A (ja) * | 2009-06-19 | 2012-12-06 | テバ ファーマシューティカル インダストリーズ リミティド | 多発性硬化症のラキニモドでの治療 |
| EP2982371A1 (en) | 2010-02-12 | 2016-02-10 | Biogen MA Inc. | Dimethyl fumarate with glatiramer acetate or interferon-beta for treating multiple sclerosis |
| MX340734B (es) * | 2011-01-25 | 2016-07-22 | Novartis Ag | Sistemas y metodos de captura y formacion de imagenes de movimiento para uso medico. |
| AR090885A1 (es) * | 2012-05-02 | 2014-12-10 | Teva Pharma | Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple |
-
2013
- 2013-03-13 US US13/800,047 patent/US20130259856A1/en not_active Abandoned
- 2013-03-25 AR ARP130100966 patent/AR090491A1/es unknown
- 2013-03-25 TW TW102110549A patent/TW201343164A/zh unknown
- 2013-03-26 SG SG10201607976WA patent/SG10201607976WA/en unknown
- 2013-03-26 HK HK15106555.7A patent/HK1205941A1/xx unknown
- 2013-03-26 CN CN201610252021.1A patent/CN105853422A/zh active Pending
- 2013-03-26 WO PCT/US2013/033885 patent/WO2013148690A1/en not_active Ceased
- 2013-03-26 SG SG11201405755QA patent/SG11201405755QA/en unknown
- 2013-03-26 KR KR20147030064A patent/KR20150003765A/ko not_active Withdrawn
- 2013-03-26 EA EA201491773A patent/EA201491773A1/ru unknown
- 2013-03-26 JP JP2015503465A patent/JP2015512406A/ja not_active Withdrawn
- 2013-03-26 CN CN201380016933.3A patent/CN104470520A/zh active Pending
- 2013-03-26 MX MX2014011616A patent/MX2014011616A/es unknown
- 2013-03-26 EP EP13768294.4A patent/EP2830623A4/en not_active Withdrawn
- 2013-03-26 CA CA 2868259 patent/CA2868259A1/en not_active Abandoned
- 2013-03-26 AU AU2013239850A patent/AU2013239850A1/en not_active Abandoned
- 2013-04-02 UY UY34720A patent/UY34720A/es not_active Application Discontinuation
-
2014
- 2014-09-16 IL IL234687A patent/IL234687A0/en unknown
- 2014-10-23 ZA ZA2014/07722A patent/ZA201407722B/en unknown
-
2015
- 2015-01-05 US US14/589,684 patent/US20150119420A1/en not_active Abandoned
- 2015-09-14 US US14/853,826 patent/US20160000774A1/en not_active Abandoned
-
2017
- 2017-04-24 US US15/495,406 patent/US20170224675A1/en not_active Abandoned
- 2017-05-26 JP JP2017104051A patent/JP2017200927A/ja not_active Withdrawn
- 2017-07-27 US US15/662,165 patent/US20170319570A1/en not_active Abandoned
- 2017-11-03 US US15/803,017 patent/US20180050031A1/en not_active Abandoned
-
2018
- 2018-01-04 AU AU2018200065A patent/AU2018200065A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN105853422A (zh) | 2016-08-17 |
| EP2830623A1 (en) | 2015-02-04 |
| AU2013239850A1 (en) | 2014-11-06 |
| CA2868259A1 (en) | 2013-10-03 |
| KR20150003765A (ko) | 2015-01-09 |
| TW201343164A (zh) | 2013-11-01 |
| EA201491773A1 (ru) | 2015-02-27 |
| IL234687A0 (en) | 2014-11-30 |
| EP2830623A4 (en) | 2015-09-02 |
| UY34720A (es) | 2013-10-31 |
| JP2015512406A (ja) | 2015-04-27 |
| MX2014011616A (es) | 2014-10-17 |
| US20180050031A1 (en) | 2018-02-22 |
| US20170319570A1 (en) | 2017-11-09 |
| US20130259856A1 (en) | 2013-10-03 |
| AU2018200065A1 (en) | 2018-02-01 |
| JP2017200927A (ja) | 2017-11-09 |
| CN104470520A (zh) | 2015-03-25 |
| WO2013148690A1 (en) | 2013-10-03 |
| SG11201405755QA (en) | 2014-10-30 |
| SG10201607976WA (en) | 2016-11-29 |
| AR090491A1 (es) | 2014-11-19 |
| US20170224675A1 (en) | 2017-08-10 |
| ZA201407722B (en) | 2016-06-29 |
| US20150119420A1 (en) | 2015-04-30 |
| US20160000774A1 (en) | 2016-01-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1205941A1 (en) | Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate | |
| HK1199820A1 (en) | Treatment of multiple sclerosis with combination of laquinimod and fingolimod | |
| HK1198279A1 (en) | Treatment of multiple sclerosis with combination of laquinimod and glatiramer acetate | |
| HK1198278A1 (en) | Treatment of multiple sclerosis with combination of laquinimod and interferon-beta | |
| HK1203356A1 (en) | Pharmaceutical combinations comprising a thionucleotide analog | |
| WO2015095811A8 (en) | Combination therapy with neoantigen vaccine | |
| IN2015DN03219A (https=) | ||
| WO2013188847A8 (en) | Compositions and methods for transmucosal absorption | |
| HK1211483A1 (en) | Combination of rasagiline and pridopidine for treating neurodegenerative disorders, in particular huntington's disease | |
| HK1209672A1 (en) | Treatment of multiple sclerosis with combination of laquinimod and fampridine | |
| HK1218251A1 (zh) | 用拉喹莫德治疗多发性硬化症 | |
| HK1218865A1 (zh) | 用於降低多发性硬化症中丘脑损伤的拉喹莫德 | |
| GB2497453B8 (en) | Pharmaceutical composition and methods of treating and preventing the diseases caused by HIV or associated with HIV | |
| HK1220136A1 (zh) | 治疗b2-缓激肽受体介导的血管性水肿的方法 | |
| HK1223855A1 (zh) | 拉喹莫德和氟吡汀组合物用於治疗多发性硬化症 | |
| WO2013038200A3 (en) | Neurodevelopmental disorders | |
| WO2013074050A3 (en) | Magnetic diffusional patch | |
| HK1208356A1 (en) | Methods of maintaining, treating or improving cognitive function | |
| HUE040124T2 (hu) | Diaminooxidázt tartalmazó helyi alkalmazású kompozíciók, magas hisztamin-szinttel társult, a fájdalom növekedésével járó betegségek kezelésére vagy megelõzésére | |
| PH12014500252A1 (en) | Treatment of multiple sclerosis with combination of laquinimod and glatiramer acetate | |
| HK1227691A1 (zh) | 利用拉喹莫德和特立氟胺的组合来治疗多发性硬化症 | |
| WO2015065628A3 (en) | Laquinimod combination therapy for treatment of multiple sclerosis | |
| WO2014170820A3 (en) | A pharmaceutical combination for treating tuberculosis | |
| HK1223854A1 (zh) | 通过阿仑单抗诱导随後通过拉喹莫德疗法来治疗多发性硬化症 | |
| AR088093A1 (es) | Tratamiento de la esclerosis multiple con una combinacion de laquinimod y acetato de glatiramer |